Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc (Nasdaq: ORMP) is transforming medication delivery through its pioneering oral protein therapeutics platform. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trials, strategic partnerships, and regulatory developments related to the company's innovative POD™ technology.
Access timely announcements about oral insulin progress, diabetes treatment innovations, and collaborative ventures like the OraTech partnership. Our curated collection features earnings reports, trial result disclosures, and manufacturing updates while maintaining strict compliance with financial disclosure standards.
Key content categories include:
- Clinical trial milestones for oral biologic therapies
- Technology licensing agreements
- Financial performance updates
- Strategic collaborations in drug development
Bookmark this page for direct access to Oramed's official communications and verified third-party reporting. For comprehensive tracking of this clinical-stage biopharmaceutical innovator, consider subscribing to our news alert service.
On February 9, 2023, Oramed Pharmaceuticals (Nasdaq: ORMP) provided a shareholder update, emphasizing its ongoing analysis of data from its halted Phase 3 oral insulin trials. The management and Board are currently reviewing the company's pipeline and exploring strategic alternatives to enhance shareholder value, including potential mergers or acquisitions. CEO Nadav Kidron stated the clinical team will analyze the unblinded Phase 3 data to determine the future of their oral insulin assets and platform technology. No timetable for completion has been established, nor can any assurance be given that the review will yield a transaction.
Oramed Pharmaceuticals announced negative top-line results from its Phase 3 trial (ORA-D-013-1) of ORMD-0801 for Type 2 Diabetes, involving 710 patients over 26 weeks. The trial failed to meet both primary and secondary endpoints for improving glycemic control and fasting plasma glucose levels. Consequently, Oramed plans to discontinue its oral insulin clinical activities for Type 2 Diabetes. The CEO expressed disappointment but acknowledged the prior positive trial results, indicating that future updates will follow as data is analyzed.
FAQ
What is the current stock price of Oramed Pharmaceuticals (ORMP)?
What is the market cap of Oramed Pharmaceuticals (ORMP)?
